Assessing the Impact of PD1 Checkpoint Blockade in a Murine Model of Bladder Cancer by Immunophenotypic & Molecular Profiles

Time: 4:40 pm
day: Day One


  • Bladder cancer is the tenth leading cause of cancer-related deaths worldwide. Five checkpoint immunotherapies that target the PD-1/PD-L1 axis are FDA approved, and gene- and protein-based approaches are helping to identify new combination treatment strategies for therapeutic intervention.
  • Using the murine MB49 model for bladder cancer, NanoString® and flow cytometry were used to provide gene and cell-specific signatures of the tumor microenvironment (TME) in response to checkpoint blockade by anti-mPD-1.
  • NanoString® and flow analyses were complementary and demonstrated evidence of T cell recruitment and upregulation of genes associated with anti-tumor activity as well as a number of biomarkers suggestive of immunosuppression. These data can be used mechanistically and to inform rational combination strategies.